Results 2,921-2,940 of 3,998 for speaker:Michael Harty

Joint Oireachtas Committee on Health: Home Care - Rights, Resources and Regulation: Discussion (15 Nov 2017)

Michael Harty: Thank you very much. Are there any further questions?

Joint Oireachtas Committee on Health: Home Care - Rights, Resources and Regulation: Discussion (15 Nov 2017)

Michael Harty: Of course it would also be possible to include some compensation for the variation in hours into the funding mechanism as well. That would be another way to look at it. If a person was opposed to the social welfare system, it could be looked at from another angle and tailor the contracts of employment and also the funding to exactly match with that. However, the nature of the work does not...

Written Answers — Department of Health: Health Care Policy (15 Nov 2017)

Michael Harty: 73. To ask the Minister for Health the legislative proposals he plans to bring forward in collaboration with other Departments to protect vulnerable adults from abuse; and if he will make a statement on the matter. [44410/17]

Multi-Party Actions Bill 2017: Second Stage (14 Nov 2017)

Michael Harty: I will lead off. I would like to speak in favour of this Bill. The proposal in this Bill is broadly similar to what are known as class actions in the United States and, thus, is worth considering seriously. Clearly, there are a number of advantages associated with this form of litigation. However, there are also some disadvantages but I will deal with advantages first. As has been...

Written Answers — Department of Health: Hospital Waiting Lists (14 Nov 2017)

Michael Harty: 288. To ask the Minister for Health when a person (details supplied) in County Clare will receive a date for surgery; and if he will make a statement on the matter. [47740/17]

Written Answers — Department of Health: Hospital Appointments Status (14 Nov 2017)

Michael Harty: 289. To ask the Minister for Health further to Parliamentary Question No. 439 of 3 October 2017, the reason a person (details supplied) in County Clare has had surgery cancelled at University Hospital Limerick; when the person will receive a new appointment; and if he will make a statement on the matter. [47741/17]

Cannabis for Medicinal Use Regulation Bill 2016 Report: Motion [Private Members] (9 Nov 2017)

Michael Harty: I am in a very difficult position, as I was when the debate was conducted on 1 December last year. At the time I saw fundamental flaws in the Bill and I was the only person in the Chamber that night to speak against it. I spoke on it from a position of genuinely held medical views, which I still hold. I am also here as the Chairman of the health committee, which is proposing the motion...

Cannabis for Medicinal Use Regulation Bill 2016 Report: Motion [Private Members] (9 Nov 2017)

Michael Harty: I will need 15 minutes.

Cannabis for Medicinal Use Regulation Bill 2016 Report: Motion [Private Members] (9 Nov 2017)

Michael Harty: I move:That Dáil Éireann accepts the recommendation of the Joint Committee on Health in its Report entitled 'Report on Scrutiny of the Cannabis for Medicinal Use Regulation Bill 2016 [PMB]', copies of which were laid before Dáil Éireann on 12th July 2017, that the Bill should not proceed to Committee Stage for the reasons set out in the Report, and orders accordingly. I...

Written Answers — Department of Public Expenditure and Reform: Public Sector Pay (9 Nov 2017)

Michael Harty: 28. To ask the Minister for Public Expenditure and Reform the measures he plans to put it place to unwind the Financial Emergency Measures in the Public Interest Act 2015 as applied to contract holders that are not part of the public service; and if he will make a statement on the matter. [47152/17]

Joint Oireachtas Committee on Health: Business of Joint Committee (8 Nov 2017)

Michael Harty: As we have quorum I wish to call the meeting to order. I propose that we go into private session to deal with housekeeping matters. Is that agreed? Agreed.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: The purpose of this morning's meeting is to engage with the HSE and the National Centre for Pharmacoeconomics, NCPE, regarding the processes involved in evaluating orphan drugs. On behalf of the committee, I welcome Mr. John Hennessy, national director of primary care, and Mr. Shaun Flanagan, chief pharmacist at the corporate pharmaceutical unit, from the HSE and, from the NCPE, Professor...

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: I thank Mr. Hennessy. I call on Professor Barry to make his opening remarks.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: I thank Professor Barry. We will take members in groups of three, so I ask the witnesses to make a note of the various questions that are submitted. We will take Deputies Louise O'Reilly, Margaret Murphy O'Mahony and Billy Kelleher.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: I propose that we suspend the meeting briefly until we clarify the source of the sound.

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: We will resume. Does Deputy Kelleher want to rephrase his question?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: Would Mr. Hennessy like to come in?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: Professor Barry stated the Food and Drug Administration, FDA, did not approve Translarna. Are we looking at the FDA or the European Medicines Agency, EMA? What is the view of the European Medicines Agency of Translarna?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: Why would one look to the FDA rather than the EMA?

Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (8 Nov 2017)

Michael Harty: We have others who are yet to contribute.